UNIVERSITY OF MANCHESTER
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 2004-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://manchester.ac.uk
Clinical Trials
192
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
St Mary's Assisted Reproductive Technology and Cardiometabolic Health: Modifiable Targets for Multimorbidity Prevention (START-HEALThY)
- Conditions
- Maternal Cardiometabolic HealthInfertilityAssisted Reproductive TechnologyCardiovascular HealthMetabolic Healthin Vitro Fertilisation
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 120
- Registration Number
- NCT07173569
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\)Left Ventricular Outflow Tract ObstructionMyocardial Ischaemia
- Interventions
- Drug: Camzyos (Mavacamten)
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 75
- Registration Number
- NCT07120776
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care
- Conditions
- Patient Safety Concerns
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 10000
- Registration Number
- NCT07084090
Low Calorie Sweeteners Effects on Appetite
- Conditions
- Appetite
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 17
- Registration Number
- NCT07018921
- Locations
- 🇬🇧
University of Manchester, Manchester, United Kingdom
Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis
- Conditions
- Respiration DisordersRespiratory FailureSepsisInfection in ICUPneumonia
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 119
- Registration Number
- NCT06977165
- Locations
- 🇬🇧
The University of Manchester, Manchester, Lancashire, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 39
- Next
News
Poolbeg Pharma Advances POLB 001 Phase 2a Trial to Prevent Cytokine Release Syndrome in Multiple Myeloma
Poolbeg Pharma has secured Accelerating Clinical Trials Limited to conduct the POLB 001 Phase 2a trial and obtained free supply of an approved bispecific antibody drug for the study.
AeroRx Therapeutics Reports Positive Phase 2a Results for First Nebulized LABA/LAMA Combination Therapy AERO-007 in COPD
AeroRx Therapeutics announced positive Phase 2a proof-of-concept results for AERO-007, the first nebulized LABA/LAMA combination therapy in development for COPD maintenance treatment.
Weight Gain Combined with Delayed Motherhood Nearly Triples Breast Cancer Risk, Study Finds
New research reveals women who gain significant weight after age 20 and delay childbirth until after 30 (or remain childless) face a 2.7 times higher risk of developing breast cancer.
Weight Loss Injections Show Promising Anti-Cancer Effects Beyond Weight Reduction
Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.
Advancements in Gene Therapy Approaches for Neuromuscular Diseases: Promises and Challenges
Gene therapy is transforming treatment for neuromuscular diseases, with AAV-mediated approaches offering multiple strategies including adding, silencing, or editing genes depending on disease mechanisms.
Procalcitonin-Guided Protocol Shortens Antibiotic Use in Sepsis Treatment
A UK trial demonstrates that a procalcitonin (PCT)-guided protocol can safely reduce antibiotic duration in sepsis patients by 10% compared to standard care.